Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
Can you apply?
This grant is for researchers investigating schizophrenia and related disorders in mid-to-late-life populations. Eligible applicants include academic institutions, research hospitals, nonprofit research organizations, and other entities with institutional research capacity. Applicants must be able to demonstrate institutional support, secure necessary IRB/ethics approvals, and maintain compliance with federal research regulations. The R21 mechanism specifically supports exploratory/developmental research that is novel or high-risk, with clinical trial as an optional component. Geographically, applications may be submitted from U.S. institutions and some international collaborations, though funding typically flows to U.S.-based research entities. Activities supported include preliminary data collection, feasibility studies, protocol development, and clinical trials examining interventions, mechanisms, or outcomes related to schizophrenia in aging populations.
Program description
Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
How to apply
Application links
Required documents
- SF-424 R&R (federal application form)
- Project Narrative and Specific Aims (typically 6-15 pages depending on NOFO)
- Research Strategy (experimental design, methodology, statistical approach)
- Budget Justification and detailed budget narrative
- Biographical sketches of key personnel (NIH format)
- Letters of institutional support and resource availability
- IRB/ethics approval or evidence of regulatory compliance plan
- Clinical trial protocol (if clinical trial component is included)
- NIH Inclusion Enlistment Plan (human subjects, women, minorities, children as applicable)
- Letters of support from collaborating institutions or clinical sites (if applicable)
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.242 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$75,056,208
-
$74,756,329
-
$72,845,834
-
$64,705,159
-
$63,991,707
-
$54,214,022
-
$38,895,082
-
$38,475,557
-
$34,635,977
-
$34,475,710
Top States by Funding
- CA 15 awards $408.1M
- MA 9 awards $230.4M
- NY 6 awards $184.2M
- WA 4 awards $174.9M
- CT 3 awards $138.9M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.242). How funding has trended year over year.
| 2024 | $1,722,300,004 | |
| 2025 | $1,726,864,191 | |
| 2026 est. | $99,221,272 |
FAQ
Who can apply for this R21 grant?
Academic medical centers, universities, research hospitals, nonprofit research organizations, and other institutions with research infrastructure and IRB/ethics oversight can apply. Small businesses may also be eligible under certain NIH programs. Individual researchers typically apply through their institutional affiliated entity.
What is the deadline and how often does it occur?
The deadline for this round is September 7, 2026, with applications typically due 5:00 PM ET. R21 mechanisms often have multiple annual submission windows; consult NIH's notice of funding opportunity (NOFO) for all relevant deadlines.
What types of research activities are funded?
The R21 supports exploratory and developmental research including preliminary studies, feasibility assessments, protocol development, and clinical trials examining schizophrenia and related disorders in mid-to-late-life populations.
How competitive is this grant?
R21 mechanisms are moderately competitive. Success typically requires novel preliminary data, a clearly defined research question, and feasibility for the proposed timeline. Clinical trial components may increase competitiveness if well-justified.
What is the typical funding range?
R21 grants typically provide $275,000-$350,000 in total costs over two years, though specific amounts vary by NOFO. Budget should be justified by scope and project phase.
💡 Tips for applicants
- Start by reviewing the specific NOFO (Notice of Funding Opportunity) on grants.nih.gov to confirm current eligibility, budget caps, and any special review criteria for mid-to-late-life schizophrenia research.
- Build preliminary data early: R21s require evidence of scientific merit and feasibility. Pilot data—even small or preliminary—significantly strengthens competitiveness.
- If proposing a clinical trial, clearly articulate why it is essential to your research aims and provide realistic recruitment and retention strategies based on your population's characteristics.
- Ensure your institutional environment letter explicitly endorses the project and confirms access to necessary resources (patient populations, facilities, IRB support for a mid-to-late-life cohort).
- Address the aging-specific context: explain how mid-to-late-life schizophrenia differs from early-onset disease and why your proposed approach is appropriate for this population.
⚠️ Common mistakes
Applicants often underestimate the complexity of recruiting and retaining mid-to-late-life populations with schizophrenia, leading to unrealistic timelines. Another frequent error is failing to provide sufficient preliminary or feasibility data—R21s are developmental grants that need to demonstrate scientific foundation and proof-of-concept. Additionally, weak institutional commitment or unclear access to necessary clinical populations (inpatient units, community mental health centers, geriatric psychiatry programs) undermines the application.
Similar grants
- OPEN Rural Community Health Integration2026 — New York State Department of Health
- OPEN FY26 Bureau of Land Management Rangeland Resource Management – Bureau wide — Bureau of Land Management
- OPEN FY26 Bureau of Land Management Cultural and Paleontological Resource Management – Bureau wide — Bureau of Land Management
- OPEN FY26 Bureau of Land Management Youth Conservation Corps – Bureau wide — Bureau of Land Management
- OPEN Infertility Training Center — Office of the Assistant Secretary for Health